Caricamento...
Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study
BACKGROUND/AIM: Lysozyme (mucopeptide N-acetyl-muramyl hydrolase) is widely used as a mucolytic and anti-inflammatory agent in Japan. We evaluated the effects of long-term lysozyme administration on COPD exacerbation. METHODS: In a 1-year, randomized, double-blind, placebo-controlled, parallel trial...
Salvato in:
| Pubblicato in: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4846053/ https://ncbi.nlm.nih.gov/pubmed/27143873 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S103105 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|